Antiviral therapeutics company Chimerix has received a federal contract that could reach $81 million in value if the company successfully develops a medical countermeasure to a smallpox bioterrorism agent.
The contract awarded by the Biomedical Advanced Research and Development Authority, or BARDA, gives Durham, North Carolina-based Chimerix $24.8 million during the contract’s first year. The announcement comes on the heels of a Feb. 14 announcement that the company has completed a $45 million series F round of fundraising.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Chimerix is studying an antiviral drug candidate that for now is called CMX001. While the compound is in mid-stage clinical trials as a broad-spectrum antiviral, CMX001 also has shown potential against double-stranded DNA (dsDNA) viruses that cause morbidity and mortality in humans, including smallpox. The BARDA grant builds on $37 million in grant funding that Chimerix previously received from the National Institutes of Allergy and Infectious Diseases, a part of the National Institutes of Health. That funding was also directed toward development of CMX001 as a smallpox treatment.
Chimerix said that the BARDA contract will support expanded clinical studies of CMX001, including a recently started study of the compound for the treatment of 12 life-threatening or serious conditions caused by dsDNA viruses.
Related articles
- Antiviral pharma Chimerix raises $45M in series F venture round (medcitynews.com)
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
